Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1748-717X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer ; volume:7 ; number:1 ; day:23 ; month:5 ; year:2012 ; pages:1-13 ; date:12.2012
Radiation oncology ; 7, Heft 1 (23.5.2012), 1-13, 12.2012
- Creator
-
Røe, Kathrine
- Contributor
-
Mikalsen, Lars TG
van der Kogel, Albert J.
Bussink, Johan
Lyng, Heidi
Ree, Anne H.
Marignol, Laure
Olsen, Dag R.
SpringerLink (Online service)
- DOI
-
10.1186/1748-717X-7-75
- URN
-
urn:nbn:de:1111-2016072617754
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Røe, Kathrine
- Mikalsen, Lars TG
- van der Kogel, Albert J.
- Bussink, Johan
- Lyng, Heidi
- Ree, Anne H.
- Marignol, Laure
- Olsen, Dag R.
- SpringerLink (Online service)
Other Objects (12)
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy
Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer
Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study
Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer
Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR)
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy
Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer
Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study
Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer
Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR)
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy
Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer
Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study
Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer
Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR)
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer